Research Article

Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study

Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

‡These two authors contributed equally

Search for more papers by this author

Mengxia Mao‡

Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

‡These two authors contributed equally

Search for more papers by this author

Yonghua Yang

Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

Search for more papers by this author

Zhiqiang Cai

Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

Search for more papers by this author

Yan Li

Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

Search for more papers by this author

Yuanyuan Chen

Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

Search for more papers by this author

Jun Cai

*Author for correspondence:

E-mail Address: caijun0540@163.com

https://orcid.org/0000-0002-7503-3427

Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

Search for more papers by this author

Qingqing Ye

**Author for correspondence:

E-mail Address: zhiyin0540@163.com

Department of Breast Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou City, Hubei Province, China, 434000

Search for more papers by this author

Published Online:31 Aug 2023https://doi.org/10.2217/fon-2023-0470

View article

Abstract

Objective: To investigate the safety and efficacy of anlotinib hydrochloride capsules in stage III–IV non-small-cell lung cancer (NSCLC). Methods: NSCLC patients received anlotinib monotherapy or combination therapy. The primary end point was adverse reactions during anlotinib treatment and the secondary end point was progression-free survival. Results: During anlotinib treatement, 41.85% (167/399) of patients experienced adverse reactions, and the monotherapy group had a lower incidence than the combination group (36.89 vs 49.68%; p = 0.012). The median progression-free survival of patients in the monotherapy group was significantly lower than that in the combination group (5 vs 6 months; p = 0.0119). Conclusion: Compared with anlotinib monotherapy, combination therapy resulted in longer PFS and a higher incidence of adverse reactions in patients with NSCLC.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.) 134(7), 783–791 (2021).
MedlineGoogle Scholar
2. Wu F, Wang L, Zhou C. Lung cancer in China: current and prospect. Curr. Opin. Oncol. 33(1), 40–46 (2021).
Medline CASGoogle Scholar
3. Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. (Lond.) 42(10), 937–970 (2022).
Google Scholar
4. Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit. Rev. Oncol. Hematol. 157, doi:10.1016/j.critrevonc.2020.103194 (2021) (Epub ahead of print).
MedlineGoogle Scholar
5. Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125), 1023–1075 (2018).
MedlineGoogle Scholar
6. Rusch VW, Chansky K, Kindler HL et al. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J. Thorac. Oncol. 11(12),2112–2119 (2016).
MedlineGoogle Scholar
7. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance.Annu. Rev. Pathol. 16, 223–249 (2021)
Medline CASGoogle Scholar
8. Dall'Olio FG, Marabelle A, Caramella C et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 19(2), 75–90 (2022).
MedlineGoogle Scholar
9. Shen G, Zheng F, Ren D et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 11(1), 120 (2018).
MedlineGoogle Scholar
10. Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene 654, 77–86 (2018).
Medline CASGoogle Scholar
11. Liang L, Hui K, Hu C et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res. 38(1), 71 (2019).
MedlineGoogle Scholar
12. Lu J, Zhong H, Chu T et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur. Respir. J. 53(3), doi:10.1183/13993003.01562-2018 (2019) (Epub ahead of print).
Google Scholar
13. Song F, Hu B, Cheng JW et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell. Death Dis. 11(7), 573 (2020).
Medline CASGoogle Scholar
14. Xu P, Wang H, Pan H, Chen J, Deng C. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. Cancer Chemother. Pharmacol. 89(2), 183–196 (2022).
Medline CASGoogle Scholar
15. Zhou AP, Bai Y, Song Y et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist 24(8), e702–e708 (2019). • Comparing the clinical efficacy of anlotinib versus sunitinib as a first-line drug treatment for malignant tumors, and has reference significance for the treatment of lung cancer.
Medline CASGoogle Scholar
16. Yang D, Chen F, Gong D et al. Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib. Pediatr. Surg. Int. 38(3), 465–472 (2022). • The antitumor activities of anlotinib, oxaliplatin and sorafenib are compared in animal models to provide a reference for in-depth understanding of the antitumor molecular mechanism of anlotinib.
MedlineGoogle Scholar
17. Genestreti G, Grossi F, Genova C et al. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncol. 10(13), 2081–2096 (2014). • A review of the research progress of third- and fourth-line clinical treatment in patients with advanced non-small-cell lung cancer.
CASGoogle Scholar
18. Galetta D, Rossi A, Colucci G, Gebbia V. Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option? Oncology 77(Suppl. 1), S113–S121 (2009).
Medline CASGoogle Scholar
19. Han B, Li K, Wang Q et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4(11), 1569–1575 (2018). •• A previous study investigating the clinical efficacy of anlotinib as a third-line or subsequent drug for lung cancer.
MedlineGoogle Scholar
20. Zheng HR, Jiang AM, Gao H et al. The efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study. Cancer Manag. Res. 14, 2273–2287 (2022). •• A recently published study exploring the clinical efficacy of anlotinib in the treatment of non-small-cell lung cancer in a real-world, multicenter study.
MedlineGoogle Scholar
21. Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. Curr. Oncol. 25(Suppl. 1), S45–S58 (2018).
Medline CASGoogle Scholar
22. Cortot AB, Audigier-Valette C, Molinier O et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: results of the IFCT-1103 ULTIMATE study. Eur. J. Cancer 131, 27–36 (2020).
Medline CASGoogle Scholar
23. Rui M, Li H. Cost–effectiveness of osimertinib vs docetaxel-bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China. Clin. Ther. 42(11), 2159–2170.e6 (2020).
Medline CASGoogle Scholar
24. Shen F, Li J, Liu F et al. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis. Fron. Oncol. 13, doi:10.3389/fonc.2023.1095362 (2023) (Epub ahead of print). • A recently published study exploring the clinical efficacy and adverse effects of anlotinib in the treatment of high-grade glioma carcinoma.
Google Scholar
25. Lv B, Chen J, Liu XL. Anlotinib-induced hypertension: current concepts and future prospects. Curr. Pharm. Des. 28(3), 216–224 (2022). • A study of anlotinib treatment of induced hypertension.
Medline CASGoogle Scholar
26. Sun Y, Niu W, Du F et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol. 9(1), 105 (2016). •• A study of anlotinib in the treatment of solid tumors, including clinical efficacy, adverse effects, pharmacokinetics and antitumor mechanisms.
MedlineGoogle Scholar

Vol. 19, No. 25

Metrics

Downloaded 38 times

History

Received 26 May 2023

Accepted 8 August 2023

Published online 31 August 2023

Published in print August 2023

Information

Keywords

Author contributions

Conceptualization: J Cai and Q Ye; data curation: M Wang and M Mao; formal analysis: Y Yang and Z Cai; investigation: Y Li; methodology: Y Chen; writing – original draft: M Wang and M Mao; writing – review and editing: J Cai and Q Ye.

Financial & competing interests disclosure

This research was supported by the Hubei Provincial Science and Technology Plan Key Project (Special Project on Big Health; No. 2022BCE038) and the Yangtze University Joint Fund (No. WJ2019-25). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download